FGFR inhibitors hold significant clinical potential in iCCA patients, as they effectively inhibit the FGF signaling driven by FGFR2 gene fusions or rearrangements, resulting in favorable therapeutic responses (Katoh et al., 2024). Here, FGFR2 is linked to infantile convulsions and choreoathetosis.